Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Gideon Lack, Evelina Children's Hospital, London, UK
LEAP Trio is a follow-up to the LEAP study of early peanut consumption. LEAP Trio will investigate the durability of tolerance to peanut allergen in LEAP participants at age 12, development of peanut allergy in younger siblings of LEAP participants, and parental characteristics that may impact development of food allergy.
David Fox, MD , University of Michigan , Ann Arbor, MI
Dinesh Khanna, MD , University of Michigan , Ann Arbor, MI
BRAVOS is a clinical trial evaluating Brentuximab Vendotin treatment for Diffuse Cutaneous Systemic Sclerosis.
Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
Laurence Turka, MD, Massachusettes General Hospital, Boston, MA
ALLTOL is an observational clinical study to learn more about tolerance in organ transplantation.
James Markmann, MD, PhD, Massachusettes General Hospital, Boston, MA
OPTIMAL is a clinical trial that will be investigating immunosuppression withdrawal in liver transplant recipients.
Betty Diamond, MD, Feinstein Institute, Manhasset, NY
David Wofsy, MD, University of California San Francisco, San Francisco, CA
The objective of the CALIBRATE study is to determine if treating lupus nephritis with a combination of rituximab (Rituxan®) and cyclophosphamide (Cytoxan®), or a combination of rituximab and cyclophosphamide followed by treatment with belimumab (Benlysta®) is safe and if this drug combination can block the immune system attacks on the kidney.
Stephen Durham, MD, Imperial College London, London, UK
Piyush Patal, MD, Inflamax Research, Ontario, Canada
The goal of the CAT EEC study is to directly compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.
Carla Greenbaum, MD, Benaroya Research Institute, Seattle, WA
Jane Buckner, MD, Benaroya Research Institute, Seattle, WA
EXTEND is a clinical research study that will test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes.
Jonathan Corren, MD, University of California, Los Angeles, Los Angeles, CA
CATNIP is a clinical research trial, which will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen. This study will implement the concept referred to as “allergen-plus,” which aims to enhance the disease-modifying mechanisms of allergen-specific immunotherapy by combining it with other anti-inflammatory or immune-modulating agents.
James Krueger, MD, PhD, Rockefeller University, New York, NY
PAUSE is a clinical trial testing the effectiveness of ustekinumab (STELARA ®) followed by an investigational drug, abatacept, for the treatment of psoriasis. The main goal of the study is to determine the efficacy of abatacept to induce prolonged remission.
Lode Swinnen, MD, Johns Hopkins Hospital, Baltimore, MD
This trial is a phase II, single arm, open-label, single center study to assess the ability of a specialized pre-transplant conditioning regimen, bone marrow transplantation and high dose post-transplant cyclophosphamide to induce tolerance and enable long-term discontinuation of immunosuppression in six kidney transplant recipients.
Wesley Burks, MD, UNC Chapel Hill, Chapel Hill, NC
IMPACT is a clinical research study testing whether daily oral exposure to a peanut product can modify peanut allergy in young children.
Stephen Durham, MD, Imperial College, London, United Kingdom
GRASS is a clinical research study looking at long-term immunity from the symptoms of hay fever. The study is testing the effectiveness of two commercially available tolerance-increasing treatments.
James Markmann, MD, Massachusetts General Hospital, Boston, MA
The purpose of the RESTARRT study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long-term immunosuppressive medication.
Mark Rigby, MD, PhD, Indiana University/Riley Hospital for Children, Indianapolis, IN
The purpose of this trial is to test whether a drug called alefacept will slow or halt destruction of the beta cells in the pancreas. If the destruction of the beta cells is stopped, the patients might be able to produce insulin on their own longer which could stop or slow the progression of their type 1 diabetes.
Samia Khoury, Harvard Medical School, Boston, MA
ACCLAIM is a Phase II clinical research trial of the safety and efficacy of abatacept in adults with relapsing-remitting multiple sclerosis (RRMS). The study is testing whether abatacept works differently from most other MS treatments, as it is more specific in the immune cells that it targets.
Richard A. Nash, Fred Hutchinson Cancer Research Center, Seattle, WA
The HALT-MS study is investigating an experimental treatment of intensive immunosuppression followed by a transplant of the participant’s own stem cells, to see whether it can stabilize multiple sclerosis. Bone marrow CD34+ stem cells are collected from the participant, and transplanted back into the body following treatment with high doses of chemotherapy drugs. This study is for individuals with relapsing-remitting or progressive-relapsing MS, who have experienced relapses while on other MS treatments.
Stephen Gitelman, University of California, San Francisco, CA
Thymoglobulin is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether Thymoglobulin treatment can halt the progression of newly diagnosed type 1 diabetes when given within 3 months of diagnosis. This study is for people aged 12-35 years old.
Sandy Feng, University of California San Francisco, San Francisco, CA
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Long-term use of these drugs places transplant recipients at higher risk of serious infections and certain types of cancer. The purpose of this study is to determine whether immunosuppressive drugs can be safely withdrawn over a minimum of 9 months from children who received liver transplants at least 4 years ago.
Abraham Shaked, University of Pennsylvania, Philidelphia, PA
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications. However, these medications can cause long-term side effects, such as infection, kidney problems, diabetes and cancer. This study is investigating whether liver transplant recipients can slowly be taken off these drugs under medical supervision.